胆囊癌辅助治疗的研究进展

摘要/Abstract

中图分类号:

R735.8

蔡晨, 龚伟. 胆囊癌辅助治疗的研究进展[J]. 外科理论与实践, 2021, 26(02): 167-170.

CAI Chen, GONG Wei. Study on gallbladder cancer adjuvant therapy[J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 167-170.

参考文献33

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6:99-109.
[3]	Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options[J]. World J Gastroenterol, 2015, 21(43):12211-12217.
[4]	Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102.
[5]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[6]	任泰, 李永盛, 耿亚军, 等. 中国2010—2017年胆囊癌治疗模式及预后分析[J]. 中华外科杂志, 2020, 58(9):E008.
[7]	Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications[J]. HPB (Oxford), 2018, 20(9):841-847.
[8]	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabineversusgemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
[9]	胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24(9):828-838.
[10]	Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer(BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673. doi:S1470-2045(18)30915-Xpmid:30922733
[11]	Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002, 95(8):1685-1695.
[12]	Edeline J, Benabdelghani M, Bertaut A, et al. Gem-citabine and oxaliplatin chemotherapy or surveillance in resected biliary tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(8):658-667. doi:10.1200/JCO.18.00050pmid:30707660
[13]	Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1versusgemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12):1950-1958. doi:S0923-7534(20)32557-6pmid:31987298
[14]	Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase Ⅱ study[J]. J Clin Oncol, 2001, 19(20):4089-4091. pmid:11600613
[15]	Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase Ⅱ trial[J]. Br J Cancer, 2002, 87(7):702-704.
[16]	Alberts SR, Al-Khatib H, Mahoney MR, et al. Gem-citabine, 5-fluorouracil, and leucovorin in advanced bi-liary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase Ⅱ trial[J]. Cancer, 2005, 103(1):111-118. pmid:15558814
[17]	Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial[J]. J Clin Oncol, 2005, 23(10):2332-2338.
[18]	Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase Ⅱ trial[J]. Br J Cancer, 2008, 98(2):309-315.
[19]	Zhang W, Du C, Sun Y, et al. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase Ⅱ trial[J]. Cancer Chemother Pharmacol, 2018, 82(4):655-660.
[20]	Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
[21]	Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6):824-830.
[22]	Yoo C, Han B, Kim HS, et al. Multicenter phase Ⅱ study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat, 2018, 50(4):1324-1330.
[23]	Wang J, Narang AK, Sugar EA, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1100-S1106.
[24]	Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease[J]. J Surg Oncol, 2007, 96(1):8-13. pmid:17516546
[25]	Hyder O, Dodson RM, Sachs T, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis[J]. Surgery, 2014, 155(1):85-93.
[26]	Mantripragada KC, Hamid F, Shafqat H, et al. Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base[J]. J Natl Cancer Inst, 2017, 109(2):djw202.
[27]	Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the national cancer data base[J]. J Gastrointest Surg, 2015, 19(10):1794-1801.
[28]	Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a syste-matic review and meta-analysis[J]. HPB (Oxford), 2017, 19(9):741-748.
[29]	Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers[J]. Cancer Discov, 2017, 7(9):943-962. doi:10.1158/2159-8290.CD-17-0245pmid:28818953
[30]	Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial[J]. Eur J Cancer, 2017, 87:122-130. doi:S0959-8049(17)31353-9pmid:29145038
[31]	Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J]. Cancer Immunol Immunother, 2019, 68(9):1527-1535.
[32]	Chen X, Wu X, Wu H, et al. Camrelizumab plus gem-citabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
[33]	Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.

胆囊癌辅助治疗的研究进展

Study on gallbladder cancer adjuvant therapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献33

相关文章15

编辑推荐

Metrics

本文评价

[1]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟.预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[2]	杨盈赤, 庞凯, 张忠涛.新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(03): 186-189.
[3]	邢颖, 程石.胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[4]	高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅.新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151.
[5]	王远江, 邹浩.胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[6]	李国立, 郭飞龙.动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.
[7]	冯梅晶, 任新平.超声造影在胆囊隆起样病变诊断中的应用进展[J]. 诊断学理论与实践, 2023, 22(01): 68-74.
[8]	何燕燕, 李凤珠.膀胱原发性上皮样血管肉瘤一例报道及文献复习[J]. 诊断学理论与实践, 2022, 21(06): 719-725.
[9]	陈小松, 沈坤炜, 李宏为.早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386.
[10]	曹璐, 郑思悦, 陈佳艺.早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410.
[11]	朱思毅综述, 陈小松, 沈坤炜审校.肥胖与早期乳腺癌预后和辅助治疗疗效的研究进展[J]. 外科理论与实践, 2022, 27(05): 468-472.
[12]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校.肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[13]	郭杨, 郭天安, 徐烨.直肠癌新辅助化疗的研究进展[J]. 外科理论与实践, 2022, 27(04): 370-374.
[14]	许梓枫综述, 宗雅萍, 陆爱国审校.局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270.
[15]	罗东凤, 游建华, 李啸扬, 李军民, 张赟翔.不耐受强化化疗的初治老年急性髓系白血病患者诱导治疗疗效及安全性[J]. 内科理论与实践, 2022, 17(03): 220-226.